Ariel Grajales-Cruz, MD

Dr. Grajales-Cruz received his MD from Universidad Central del Caribe in Bayamon, Puerto Rico. He completed an Internal Medicine Residency at Veterans Administration Caribbean Healthcare System, where he also served as Chief Resident. Most recently, he completed a Hematology and Medical Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Grajales-Cruz’s clinical and research interests include plasma cell dyscrasias, such as multiple myeloma, monoclonal gammopathy of undetermined significance, plasmacytoma, primary systemic amyloidosis and Waldenstrom macroglobulinemia.

Education & Training

Board Certification:

• -

Fellowship:

• University of South Florida / Moffitt Cancer Center - Hematology and Medical Oncology

Residency:

• Veteran's Administration Caribbean Healthcare System (VACHS) - Internal Medicine

Medical School:

• Universidad Central del Caribe (UCC) - MD

• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
• Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020 Jul.26(14):3589-3596. Pubmedid: 32198151. Pmcid: PMC8588795.
• Grajales-Cruz A, Baco-Viera F, Rive-Mora E, Ramirez-Tanchez C, Tasso D, Arroyo-Portela N, Calderon E, Padua-Octaviani IJ, Caceres-Perkins W. Primary Adrenal Angiosarcoma: A Rare and Potentially Misdiagnosed Tumor. Cancer Control. 2017 Apr.24(2):198-201. Pubmedid: 28441375. Pmcid: PMC5483322.